UBS has upgraded Biogen (BIIB) stock and raised the target price to $225, citing pipeline catalysts as a key reason for the upgrade.

UBS has upgraded Biogen (BIIB) stock, citing favorable pipeline catalysts as a key reason. The target price for Biogen shares has been raised to $225. This adjustment reflects confidence in the company's growth potential and anticipated drug approvals. The upgrade may positively influence market perception and investor interest in Biogen moving forward.

Biogen (BIIB) Stock Upgrade: Target Raised to $225 from UBS

AI Summary

Related News

ASMI Shares Surge 8.8% After Quarterly Revenue of €862.5M Reported

Qualcomm (QCOM) Coverage Reinstated by Barclays with Underweight Rating

Skyworks Solutions (SWKS) Stock Upgrade Following Apple (AAPL) Timing

Barclays Downgrades Penguin Solutions Stock Rating on Mix Shift